Multiple endocrine neoplasia type 1

Expert Review of Endocrinology and Metabolism

Volumn 4, Issue 4, 2009, Pages 371-388

  Lips, Cornelis J M ^a   Dreijerink, Koen ^a   Links, Thera P ^b   Höppener, Jo W M ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c University of Medical Center Utrecht ^*  (Netherlands)

Author keywords

DNA diagnosis; Genetic testing; MEN 1; Menin; Multiple endocrine neoplasia type 1; Mutation analysis; Periodic clinical monitoring; Presymptomatic treatment

Indexed keywords

5 HYDROXYTRYPTOPHAN; 6 FLUORODOPA F 18; ALPHA INTERFERON; ANGIOPEPTIN; CABERGOLINE; CELL NUCLEUS RECEPTOR; CINACALCET; CISPLATIN; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GROWTH HORMONE RELEASING FACTOR; KETOCONAZOLE; METHIONINE; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; PROTON PUMP INHIBITOR; QUINAGOLIDE; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN;

ACROMEGALY; ACTH SECRETING ADENOMA; ADRENAL TUMOR; CANCER SURGERY; CELL DIFFERENTIATION; CLINICAL TRIAL; CUSHING DISEASE; DIAGNOSTIC IMAGING; DNA REPAIR; EMBRYO DEVELOPMENT; ENDOCRINE TUMOR; GASTRINOMA; GENE MUTATION; GENETIC PREDISPOSITION; GENOTYPE PHENOTYPE CORRELATION; GROWTH HORMONE SECRETING ADENOMA; HEART VALVE REGURGITATION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERPARATHYROIDISM; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; INSULINOMA; LUNG CANCER; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2; MUTATIONAL ANALYSIS; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS CANCER; PANCREAS ISLET CELL TUMOR; PARATHYROID ADENOMA; PARATHYROID HYPERPLASIA; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN FUNCTION; REVIEW; STOMACH CANCER; THYMUS CANCER; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE; ZOLLINGER ELLISON SYNDROME;

EID: 69949136829     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/eem.09.22     Document Type: Review

References (150)

1. Brandi ML, Gagel RF, Angeli A et al. Consensus guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86, 5658-5671 (2001).
2. Marx SJ, Simonds WF. Hereditary hormone excess: genes, molecular pathways, and syndromes. Endocr. Rev. 26, 615-661 (2005).
3. Toledo RA, Lourenco DM, Coutinho FL et al. Novel MEN1 germline mutations in Brazilian families with multiple endocrine neoplasia type 1. Clin. Endocrinol. (Oxf.) 67, 377-384 (2007).
4. Wilkinson S, Teh BT, Davey KR, McArdle JP, Young M, Shepherd JJ. Cause of death in multiple endocrine neoplasia type 1. Arch. Surg. 128, 683-690 (1993).
5. Doherty GM, Olson JA, Frisella MM, Lairmore TC, Wells SA Jr, Norton JA. Lethality of multiple endocrine neoplasia type I. World J. Surg. 22, 581-586; discussion 586-587 (1998).
6. Lairmore TC, Piersail LD, DeBenedetti MK et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). Ann. Surg. 239, 637-645; discussion 645-647 (2004).
7. Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasia type 1. Science 276, 404-407 (1997).
8. Lemmens I, Van de Ven WJ, Kas K et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum. Mol. Genet. 6, 1177-1183 (1997).
9. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum. Mutat. 29, 22-32 (2008).
10. Larsson C, Nordenskjöld M. Family screening in multiple endocrine neoplasia type 1 (MEN 1). Ann. Med. 26, 191-198 (1994).
11. Olufemi SE, Green JS, Manickam P et al. Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland. Hum. Mutat. 11, 264-269 (1998).
12. Hao W, Skarulis MC, Simonds WF et al. Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma. J. Clin. Endocrinol. Metab. 89, 776-3784 (2004).
13. Lourenço DM Jr, Toledo RA, Mackowiak II et al. Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation, clinical features, and bone mineral density profile. Eur. J. Endocrinol. 159, 259-274 (2008).
14. Guru SC, Goldsmith PK, Burns AL et al. Menin, the product of the MEN1 gene, is a nuclear protein. Proc. Natl Acad. Sci. USA 95, 1630-1634 (1998).
15. Calender A, Giraud S, Porchet N et al. Clinicogenetic study of MEN1: recent physiopathological data and clinical applications. Study Group of Multiple Endocrine Neoplasia (GENEM). Ann. Endocrinol. (Paris) 59, 444-451 (1998).
16. La P, Desmond A, Hou Z, Silva AC et al. Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expression. Oncogene 25, 3537-3546 (2006).
17. La P, Silva AC, Hou Z et al. Direct binding of DNA by tumor suppressor menin. J. Biol. Chem. 279, 49045-49054 (2004).
18. Kim H, Lee JE, Cho EJ, Liu JO, Youn HD. Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase omplex. Cancer Res. 63, 6135-6139 (2003).
19. Yokoyama A, Wang Z, Wysocka J et al. Leukemia proco-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol. Cell. Biol. 24, 5639-5649 (2004).
20. Hughes CM, Rozenblatt-Rosen O, Milne TA et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol. Cell 13, 587-597 (2004).
21. Kornberg RD. Chromatin structure: a repeating unit of histones and DNA. Science 184, 868-871 (1974).
22. Lin SY, Elledge SJ. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113, 881-889 (2003).
23. Roguev A, Schaft D, Shevchenko A et al. The Saccharomyces cerevisiae Setl complex includes an Ash2 homologue and methylates histone 3 lysine 4. EMBO J. 20, 7137-7148 (2001).
24. Santos-Rosa H, Schneider R, Bannister AJ et al. Active genes are tri-methylated at K4 of histone H3. Nature 419, 407-411 (2002).
25. Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 14, 36-46 (2008).
26. Scacheri PC, Davis S, Odom DT et al. Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet. 2, e51 (2006).
27. Agarwal SK, Impey S, McWeeney S et al. Distribution of menin-occupied regions in chromatin specifies a broad role of menin in transcriptional regulation. Neoplasia 9, 101-107 (2007).
28. Shen HC, Rosen JE, Yang LM et al. Parathyroid tumor development involves deregulation of homeobox genes. Endocr. Relat. Cancer 15(1), 267-275 (2008).
29. Varro A, Hemers E, Archer D et al. Identification of plasminogen activator inhibitor-2 as a gastrin-regulated gene: role of Rho GTPase and menin. Gastroenterology 123, 271-280 (2002).
30. Shattuck TM, Costa J, Bernstein M, Jensen RT, Chung DC, Arnold A. Mutational analysis of Smad3, a candidate tumor suppressor implicated in TGF-β and menin pathways, in parathyroid adenomas and enteropancreatic endocrine tumors. J. Clin. Endocrinol. Metab. 87, 3911-3914 (2002).
31. Milne TA, Hughes CM, Lloyd R et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc. Natl Acad. Sci. USA 102, 749-754 (2005).
32. Karnik SK, Hughes CM, Gu X et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc. Natl Acad. Sci. USA 102, 14659-14664 (2005).
33. Franklin DS, Godfrey VL, O'Brien DA, Deng C, Xiong Y. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol. Cell. Biol. 20, 6147-6158 (2000).
34. Lin J, Jin R, Zhang B et al. Nucleolar localization of TERT is unrelated to telomerase function in human cells. J. Cell. Sci. 121, 2169-2176 (2008).
35. Cerrato A, Parisi M, Santa Anna S et al. Genetic interactions between Drosophila melanogaster menin and Jun/Fos. Dev. Biol. 298, 59-70 (2006).
36. La P, Yang Y, Karnik SK et al. Menin-mediated caspase 8 expression in suppressing multiple endocrine neoplasia type 1. J. Biol. Chem. 282, 31332-31340 (2007).
37. Jin S, Mao H, Schnepp RW et al. Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res. 63, 4204-4210 (2003).
38. Busygina V, Kottemann MC, Scott KL, Plon SE, Bale AE. Multiple endocrine neoplasia type 1 interacts with forkhead transcription factor CHES1 in DNA damage response. Cancer Res. 66, 8397-8403 (2006).
39. Sukhodolets KE, Hickman AB, Agarwal SK et al. The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene. Mol. Cell. Biol. 23, 493-509 (2003).
40. Schnepp RW, Hou Z, Wang H et al. Functional interaction between tumor suppressor menin and activator of S-phase kinase. Cancer Res. 64, 6791-6796 (2004).
41. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387, 733-736 (1997); comment in: Nature 387, 654-655 (1997).
42. Heldring N, Pawson T, McDonell D et al. Structural insights into corepressor recognition by antagonist-bound estrogen receptor. J. Biol. Chem. 282, 10449-10455 (2007).
43. Dreijerink KM, Höppener JW, Timmers HT, Lips CJ. Mechanisms of disease: multiple endocrine neoplasia type 1-relation to chromatin modifications and transcription regulation. Nat. Clin. Pract. Endocrinol. Metab. 2, 562-570 (2006).
44. Dreijerink KM, Mulder KW, Winkler GS, Höppener JW, Lips CJ, Timmers HT. Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res. 66, 4929-4935 (2006).
45. Karhu A, Aaltonen LA. Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update. Hum. Mol. Genet. 16(Spec No 1), R73-R79 (2007).
46. Georgitsi M, Heliövaara E, Paschke R et al. Large genomic deletions in AIP in pituitary adenoma predisposition. J. Clin. Endocrinol. Metab. 93, 4146-4151 (2008).
47. Laconi E. The evolving concept of tumor microenvironments. Bioessays 29, 738-744 (2007).
48. Pellegata NS, Quintanilla-Martinez L, Siggelkow H et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl Acad. Sci. USA 103, 15558-15563 (2006); erratum in: Proc. Natl Acad. Sci. USA 103, 19213 (2006).
49. Van Veelen W, Klompmaker R, Gloerich M et al. p18 is a tumor suppressor gene involved in human medullary thyroid carcinoma and pheochromocytoma development. Int. J. Cancer 124, 339-345 (2009).
50. Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J. Clin. Endocrinol. Metab. 94, 1826-1834 (2009); comment in: J. Clin. Endocrinol. Metab. 94, 1518-1520 (2009).
51. Owens M, Stals K, Ellard S, Vaidya B. Germline mutations in the CDKN1B gene encoding p27 Kip1 are a rare cause of multiple endocrine neoplasia type 1. Clin. Endocrinol. (Oxf.) 70, 499-500 (2009).
52. Igreja S, Chahal HS, Akker SA et al. Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations. Clin. Endocrinol. (Oxf.) 70, 259-264 (2009).
53. Gujral TS, van Veelen W, Richardson DS et al. A novel RET kinase-β-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma. Cancer Res. 68, 1338-1346 (2008).
54. Bai F, Pei XH, Nishikawa T, Smith MD, Xiong Y. p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors. Mol. Cell. Biol. 27, 1495-1504 (2007).
55. Roijers JF, de Wit MJ, van der Luijt RB, Ploos van Amstel HK, Höppener JW, Lips CJ. Criteria for mutation analysis in MEN 1-suspected patients: MEN 1 case-finding. Eur. J. Clin. Invest. 30, 487-492 (2000).
56. Norton JA, Venzon DJ, Berna MJ et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger - Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann. Surg. 247, 501-510 (2008).
57. Cetani F, Pardi E, Ambrogini E et al. Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. Clin. Endocrinol. (Oxf.) 64, 146-152 (2006).
58. Prager G, Kalaschek A, Kaczirek K et al. Parathyroidectomy improves concentration and retentiveness in patients with primary hyperparathyroidism. Surgery 132, 930-935; discussion: 935-936 (2002).
59. Bilezikian JP, Potts JT Jr, Fuleihan G-H et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J. Clin. Endocrinol. Metab. 87, 5353-5361 (2002).
60. Bilezikian JP, Khan AA, Potts JT Jr; Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J. Clin. Endocrinol. Metab. 94, 335-339 (2009).
61. Khan AA, Bilezikian JP, Potts JT Jr; Guest Editors for the Third International Workshop on Asymptomatic Primary Hyperparathyroidism. The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. J. Clin. Endocrinol. Metab. 94, 333-334 (2009).
62. Eastell R, Arnold A, Brandi ML et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94, 340-350 (2009).
63. Shepherd JJ, Burgess JR, Greenaway TM, Ware R. Preoperative sestamibi scanning and surgical findings at bilateral, unilateral, or minimal reoperation for recurrent hyperparathyroidism after subtotal parathyroidectomy in patients with multiple endocrine neoplasia type 1. Arch. Surg. 135, 844-848 (2000).
64. Malone JP, Srivastava A, Khardori R. Hyperparathyroidism and multiple endocrine neoplasia. Otolaryngol. Clin. North Am. 37, 715-736, viii (2004).
65. Arnalsteen L, Proye C. Surgery of hyperparathyroidism and of its potential recurrence in the MEN I setting. Ann. Chir. 128, 706-709 (2003).
66. Lambert LA, Shapiro SE, Lee JE et al. Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Arch. Surg. 140, 374-382 (2005).
67. Carling T, Udelsman R. Parathyroid surgery in familial hyperparathyroid disorders. J. Intern. Med. 257, 27-37 (2005).
68. Hubbard JG, Sebag F, Maweja S, Henry JF. Subtotal parathyroidectomy as an adequate treatment for primary hyperparathyroidism in multiple endocrine neoplasia type 1. Arch. Surg. 141, 235-239 (2006).
69. Tonelli F, Marcucci T, Fratini G, Tommasi MS, Falchetti A, Brandi ML. Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann. Surg. 246(6), 1075-1082 (2007).
70. Hessman O, Stålberg P, Sundin A et al. High success rate of parathyroid reoperation may be achieved with improved localization diagnosis. World J. Surg. 32, 774-781; discussion 782-783 (2008).
71. Faggiano A, Tavares LB, Tauchmanova L et al. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients. Clin. Endocrinol. (Oxf.) 69, 756-762 (2008).
72. Falchetti A, Cilotti A, Vagelli L et al. A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet. Nat. Clin. Pract. Endocrinol. Metab. 4(6), 351-357 (2008).
73. Klöppel G, Anlauf M. Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract. Best Pract. Res. Clin. Gastroenterol. 19, 507-517 (2005).
74. Zikusoka MN, Kidd M, Eick G, Latich I, Modlin IM. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 104, 2292-2309 (2005).
75. Kouvaraki MA, Shapiro SE, Cote GJ et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J. Surg. 30, (5) 643-653 (2006).
76. Levy-Bohbot N, Merle C, Goudet P et al. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol. Clin. Biol. 28, 1075-1081 (2004).
77. Anlauf M, Schlenger R, Perren A et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am. J. Surg. Pathol. 30, 560-574 (2006).
78. Akerstrom G, Hessman O, Hellman P, Skogseid B. Pancreatic tumours as part of the MEN-1 syndrome. Best Pract. Res. Clin. Gastroenterol. 19, 819-830 (2005).
79. Thomas-Marques L, Murat A, Delemer B et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancraeticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am. J. Gastroenterol. 101, 266-273 (2006).
80. 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 7(9), 728-734 (2006); comment in: Lancet Oncol. 7(10), 790-792 (2006).
81. 11C-5-hydroxy-tryptophan positron emission tomography. J. Clin. Oncol. 26(9), 1489-1495 (2008).
82. Hellman P, Hennings J, Akerstrom G, Skogseid B. Endoscopic ultrasonography for evaluation of pancreatic tumours in multiple endocrine neoplasia type 1. Br. J. Surg. 92, 1508-1512 (2005).
83. Triponez F, Goudet P, Dosseh D et al. Is surgery beneficial for MEN1 patients with small (≤2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? World J. Surg. 30, 654-662 (2006).
84. Tonelli F, Fratini G, Falchetti A, Nesi G, Brandi ML. Surgery for gastroenteropancreatic tumours in multiple endocrine neoplasia type 1: review and personal experience. J. Intern. Med. 257, 38-49 (2005).
85. Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH, Rothmund M. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann. Surg. 242, 757-764; discussion 764-766 (2005).
86. Tonelli F, Fratini G, Nesi G et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann. Surg. 244, 61-70 (2006).
87. Falconi M, Bettini R, Boninsegna L et al. Surgical strategy in the treatment of pancreatic neuroendocrine tumors. JOP 7, 150-156 (2006).
88. Libé R, Chanson P. Endocrine tumors of the pancreas (EPTs) in multiple endocrine neoplasia (MEN1): up-date on prognostic factors, diagnostic procedures and treatment. Ann. Endocrinol. (Paris) 68(Suppl. 1), 1-8 (2007); erratum in: Ann. Endocrinol. (Paris) 69, 459-460 (2008).
89. Viola KV, Sosa JA. Current advances in the diagnosis and treatment of pancreatic endocrine tumors. Curr. Opin. Oncol. 17, 24-27 (2005).
90. Hoffmann KM, Gibril F, Entsuah LK, Serrano J, Jensen RT. Patients with multiple endocrine neoplasia type 1 with gastrinomas have an increased risk of severe esophageal disease including stricture and the premalignant condition, Barrett's esophagus. J. Clin. Endocrinol. Metab. 91, 204-212 (2006).
91. Geerdink EA, Van der Luijt RB, Lips CJ. Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? Eur. J. Endocrinol. 149, 577-582 (2003).
92. Imamura M, Komotol, Ota S. Changing treatment strategy for gastrinoma in patients with ZES. World J. Surg. 30, 1-11 (2006).
93. Tomassetti P, Campana D, Piscitelli L et al. Treatment of Zollinger - Ellison syndrome. World J. Gastroenterol. 21, 5423-5432 (2005).
94. Granberg D, Jacobsson H, Oberg K, Gustavsson J, Lehtihet M. Regression of a large malignant gastrinoma on treatment with sandostatin LAR: a case report. Digestion 77, 92-95 (2008).
95. Wang HS, Oh DS, Ohning GV, Pisegna JR. Cyto-reduction of neuroendocrine tumours using Sandostatin LAR in combination with Infergen: results of a case series. J. Pharm. Pharmacol. 58, 1623-1628 (2006).
96. 18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients J. Clin. Endocrinol. Metab. 92, 1237-1244 (2007).
97. Biermasz NR, Smit JW, Pereira AM, Frölich M, Romijn JA, Roelfsema F. Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. Pituitary 10, 237-249 (2007).
98. Ferolla P, Faggiano A, Mansueto G et al. The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers. J. Endocrinol. Invest. 31, 277-286 (2008).
99. Rix M, Hertel NT, Nielsen FC et al. Cushing's disease in childhood as the first manifestation of multiple endocrine neoplasia syndrome type 1. Eur. J. Endocrinol. 151, 709-715 (2004).
100. Stratakis CA, Schussheim DH, Freedman SM et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 85, 4776-4780 (2000).
101. Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary 8, 3-6 (2005).
102. Vierimaa O, Georgitsi M, Lehtonen R et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312, 1228-1230 (2006).
103. Beckers A, Daly AF. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur. J. Endocrinol. 157, 371-382 (2007).
104. Benito M, Asa SL, Livolsi VA, West VA, Snyder PJ. Gonadotroph tumor associated with multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 90. 570-574 (2005).
105. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin. Endocrinol. (Oxf.) 70, 104-108 (2009).
106. Kars M, Pereira AM, Bax JJ, Romijn JA. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur. J. Endocrinol. 159(4), 363-367 (2008).
107. Higham C, Chung T, Lawrance J, Drake W, Trainer P. Long term experience of pegvisomant therapy as a treatment for acromegaly. Clin. Endocrinol. (Oxf.), DOI:10.1111/j.1365-2265.2008.03469.x (2008).
108. Bush ZM, Vance ML. Management of acromegaly: is there a role for primary medical therapy? Rev. Endocr. Metab. Disord. 9, 83-89 (2008).
109. Boscaro M, Ludlam WH, Atkinson B et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, Phase II trial. J. Clin. Endocrinol. Metab. 94, 115-122 (2009).
110. Schaefer S, Shipotko M, Meyer S et al. Natural course of small adrenal lesions in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Eur. J. Endocrinol. 158, 699-704 (2008).
111. Whitley SA, Moyes VJ, Park KM et al. The appearance of the adrenal glands on computed tomography in multiple endocrine neoplasia type 1. Eur. J. Endocrinol. 159, 819-824 (2008).
112. Waldman J, Bartsch DK, Kann PH, Fendrich V, Rothmund M, Langer P. Adrenal involvement in multiple endocrine neoplasia type 1: results of 7 years prospective screening. Langenbecks Arch. Surg. 392, 437-443 (2007).
113. Langer P, Cupisti K, Bartsch DK et al. Adrenal involvement in multiple endocrine neoplasia type 1. World J. Surg. 26, 891-896 (2002).
114. Teh BT, Zedenius J, Kytölä S et al. Thymic carcinoids in multiple endocrine neoplasia type 1. Ann. Surg. 228, 99-105 (1998).
115. Goudet P, Murat A, Cardot-Bauters C et al. The members of the GTE network. Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines). World J. Surg. 33(6), 1197-1207 (2009).
116. Ferolla P, Falchetti A, Filosso P et al. Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series. J. Clin. Endocrinol. Metab. 90, 2603-2609 (2005).
117. Gibril F, Chen YJ, Schrump DS et al. Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 88, 1066-1081 (2003).
118. Lim LC, Tan MH, Eng C, Teh BT, Rajasoorya RC. Thymic carcinoid in multiple endocrine neoplasia 1: genotype - phenotype correlation and prevention. J. Intern. Med. 259, 428-432 (2006).
119. Takagi J, Otake K, Morishita M et al. Multiple endocrine neoplasia type I and Cushing's syndrome due to an aggressive ACTH producing thymic carcinoid. Intern. Med. 45, 81-86 (2006).
120. Sachithanandan N, Harle RA, Burgess JR. Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1. Cancer 103, 509-515 (2005).
121. Norton JA, Melcher ML, Gibril F, Jensen RT. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger - Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery 136, 1267-1274 (2004).
122. Tham E, Grandell U, Lindgren E, Toss G, Skogseid B, Nordenskjöld M. Clinical testing for mutations in the MEN1 gene in Sweden: a report on 200 unrelated cases. J. Clin. Endocrinol. Metab. 92, 3389-3395 (2007).
123. Owens M, Ellard S, Vaidya B. Analysis of gross deletions in the MEN1 gene in patients with multiple endocrine neoplasia type 1. Clin. Endocrinol. (Oxf.) 68, 350-354 (2008).
124. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am. J. Med. 16, 363-371 (1954).
125. Trump D, Farren B, Wooding C et al. Clinical studies of multiple endocrine neoplasia type 1(MEN-1). Q.J. Med. 89, 653-669 (1996).
126. Ballard HS, Frame B, Hartstock RJ. Familial multiple endocrine adenoma - peptic ulcer complex. Medicine 43, 481-516 (1968).
127. Pipeleers-Marichal M, Somers G, Willems G et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger - Ellison syndrome. N. Engl. J. Med. 322, 723-727 (1990).
128. Skogseid B, Erikson B, Lundqvist G et al. Multiple endocrine neoplasia type 1: a 10 years prospective screening study in four kindreds. J. Clin. Endocrinol. Metab. 73, 281-287 (1991).
129. Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann. Int. Med. 129, 484-494 (1998).
130. Skogseid B, Larsson C, Lindgren PG et al. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 75, 76-81 (1992).
131. Vasen HF, Lamers CB, Lips CJ. Screening for the multiple endocrine neoplasia syndrome type 1: a study of 11 kindreds in the Netherlands. Arch. Int. Med. 149, 2717-2722 (1989).
132. Öberg K, Skogseid B, Eriksson B. Multiple endocrine neoplasia type 1 (MEN-1): clinical, biochemical and genetical investigations. Acta Oncol. 28, 383-387 (1989).
133. Carty SE, Helm AK, Amico JA et al. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery 124, 1106-1114 (1998).
134. Duh QY, Hybarger CP, Geist R et al. Carcinoids associated with multiple endocrine neoplasia syndromes. Am. J. Surg. 154, 142-148 (1987).
135. Teh BT, McArdle J, Chan SP et al. Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia type 1. Medicine 76, 21-29 (1997).
136. Darling TN, Skarulis MC, Steinberg SM, Marx SJ, Spiegel AM, Turner M. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch. Dermatol. 133, 853-857 (1997).
137. Vortmeyer AO, Lubensky IA, Skarulis M et al. Multiple endocrine neoplasia type 1: atypical presentation, clinical course, and genetic analysis of multiple tumors. Mod. Pathol. 12, 919-924 (1999).
138. Heppner C, Bilimoria KY, Agarwal SK et al. The tumor suppressor protein menin interacts with NF-κB proteins and inhibits NF-κB-mediated transactivation. Oncogene 20, 4917-4925 (2001).
139. Lemmens IH, Forsberg L, Pannett AA et al. Menin interacts directly with the homeobox-containing protein Pem. Biochem. Biophys. Res. Commun. 286, 426-431 (2001).
140. Kaji H, Canaff L, Lebrun JJ, Goltzman D, Hendy GN. Inactivatipn of menin, a Smad3-interacting protein, blocks transforming growth factor type β signaling. Proc. Natl Acad. Sci. USA 98, 3837-3842 (2001).
141. Chen G, A J, Wang M et al. Menin promotes the Wnt signaling pathway in pancreatic endocrine cells. Mol. Cancer Res. 6, 1894-1907 (2008).
142. Lopez-Egido J, Cunningham J, Berg M, Oberg K, Bongcam-Rudloff E, Gobl A. Menin's interaction with glial fibrillary acidic protein and vimentin suggests a role for the intermediate filament network in regulating menin activity. Exp. Cell Res. 278, 175-183 (2002).
143. Ohkura N, Kishi M, Tsukada T, Yamaguchi K. Menin, a gene product responsible for multiple endocrine neoplasia type 1, interacts with the putative tumor metastasis suppressor nm23. Biochem. Biophys. Res. Commun. 282, 1206-1210 (2001).
144. Yan J, Yang Y, Zhang H et al. Menin interacts with IQGAP1 to enhance intercellular adhesion of β-cells. Oncogene 28, 973-982 (2009).
145. Obungu VH, Lee Burns A, Agarwal SK, Chandrasekharapa SC, Adelstein RS, Marx SJ. Menin, a tumor suppressor, associates with nonmuscle myosin II-A heavy chain. Oncogene 22, 6347-6358 (2003).
146. Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg. Oncol. 12, 153-172 (2003).
147. Kidd M, Modlin IM, Black JW, Boyce M, Culler M. A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation. Regul Pept. 143, 109-117 (2007).
148. Dockray GJ. Clinical endocrinology and metabolism. Gastrin. Best Pract. Res. Clin. Endocrinol. Metab. 18, 555-568 (2004).
149. Schubert ML. Hormonal regulation of gastric acid secretion. Curr. Gastroenterol. Rep. 10, 523-527 (2008).
150. Dufner MM, Kirchhoff P, Remy C et al. The calcium-sensing receptor acts as a modulator of gastric acid secretion in freshly isolated human gastric glands. Am. J. Physiol. Gastrointest. Liver Physiol. 289, G1084-G1090 (2005).